Literature DB >> 23154795

Impact of margin size on the predicted risk of radiogenic second cancers following proton arc therapy and volumetric modulated arc therapy for prostate cancer.

Laura A Rechner1, Rebecca M Howell, Rui Zhang, Wayne D Newhauser.   

Abstract

We previously determined that the predicted risk of radiogenic second cancer in the bladder and rectum after proton arc therapy (PAT) was less than or equal to that after volumetric modulated arc therapy (VMAT) with photons, but we did not consider the impact of margin size on that risk. The current study was thus conducted to evaluate margin size's effect on the predicted risks of second cancer for the two modalities and the relative risk between them. Seven treatment plans with margins ranging from 0 mm in all directions to 6 mm posteriorly and 8 mm in all other directions were considered for both modalities. We performed risk analyses using three risk models with varying amounts of cell sterilization and calculated ratios of risk for the corresponding PAT and VMAT plans. We found that the change in risk with margin size depended on the risk model but that the relative risk remained nearly constant with margin size, regardless of the amount of cell sterilization modeled. We conclude that while margin size influences the predicted risk of a second cancer for a given modality, it appears to affect both modalities in roughly equal proportions so that the relative risk between PAT and VMAT is approximately equivalent.

Entities:  

Mesh:

Year:  2012        PMID: 23154795      PMCID: PMC3701958          DOI: 10.1088/0031-9155/57/23/N469

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  32 in total

1.  Secondary malignancies from prostate cancer radiation treatment: a risk analysis of the influence of target margins and fractionation patterns.

Authors:  Alexandru Daşu; Iuliana Toma-Daşu; Lars Franzén; Anders Widmark; Per Nilsson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-14       Impact factor: 7.038

2.  Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer.

Authors:  Dirk Wolff; Florian Stieler; Grit Welzel; Friedlieb Lorenz; Yasser Abo-Madyan; Sabine Mai; Carsten Herskind; Martin Polednik; Volker Steil; Frederik Wenz; Frank Lohr
Journal:  Radiother Oncol       Date:  2009-09-16       Impact factor: 6.280

3.  Risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer.

Authors:  Laura A Rechner; Rebecca M Howell; Rui Zhang; Carol Etzel; Andrew K Lee; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2012-10-10       Impact factor: 3.609

4.  Dosimetric impact of image-guided 3D conformal radiation therapy of prostate cancer.

Authors:  B Schaly; G S Bauman; W Song; J J Battista; J Van Dyk
Journal:  Phys Med Biol       Date:  2005-06-22       Impact factor: 3.609

5.  Maximum proton kinetic energy and patient-generated neutron fluence considerations in proton beam arc delivery radiation therapy.

Authors:  E Sengbusch; A Pérez-Andújar; P M DeLuca; T R Mackie
Journal:  Med Phys       Date:  2009-02       Impact factor: 4.071

6.  Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy.

Authors:  David Palma; Emily Vollans; Kerry James; Sandy Nakano; Vitali Moiseenko; Richard Shaffer; Michael McKenzie; James Morris; Karl Otto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

7.  Design of adaptive treatment margins for non-negligible measurement uncertainty: application to ultrasound-guided prostate radiation therapy.

Authors:  H Keller; W Tomé; M A Ritter; T R Mackie
Journal:  Phys Med Biol       Date:  2004-01-07       Impact factor: 3.609

8.  The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer.

Authors:  Uwe Schneider; Antony Lomax; Jürgen Besserer; Peter Pemler; Norbert Lombriser; Barbara Kaser-Hotz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-24       Impact factor: 7.038

9.  Potential advantages of protons over conventional radiation beams for paraspinal tumours.

Authors:  U Isacsson; H Hagberg; K A Johansson; A Montelius; B Jung; B Glimelius
Journal:  Radiother Oncol       Date:  1997-10       Impact factor: 6.280

10.  Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases.

Authors:  Pengpeng Zhang; Laura Happersett; Margie Hunt; Andrew Jackson; Michael Zelefsky; Gig Mageras
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-18       Impact factor: 7.038

View more
  3 in total

1.  Reducing the cost of proton radiation therapy: the feasibility of a streamlined treatment technique for prostate cancer.

Authors:  Wayne D Newhauser; Rui Zhang; Timothy G Jones; Annelise Giebeler; Phillip J Taddei; Robert D Stewart; Andrew Lee; Oleg Vassiliev
Journal:  Cancers (Basel)       Date:  2015-04-24       Impact factor: 6.639

2.  Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold.

Authors:  Laura Ann Rechner; Maja Vestmø Maraldo; Ivan Richter Vogelius; Xiaorong Ronald Zhu; Bouthaina Shbib Dabaja; Nils Patrik Brodin; Peter Meidahl Petersen; Lena Specht; Marianne Camille Aznar
Journal:  Radiother Oncol       Date:  2017-08-30       Impact factor: 6.280

3.  Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.

Authors:  Hunter C Gits; Maia Anderson; Stefanie Stallard; Drew Pratt; Becky Zon; Christopher Howell; Chandan Kumar-Sinha; Pankaj Vats; Katayoon Kasaian; Daniel Polan; Martha Matuszak; Daniel E Spratt; Marcia Leonard; Tingting Qin; Lili Zhao; James Leach; Brooklyn Chaney; Nancy Yanez Escorza; Jacob Hendershot; Blaise Jones; Christine Fuller; Sarah Leary; Ute Bartels; Eric Bouffet; Torunn I Yock; Patricia Robertson; Rajen Mody; Sriram Venneti; Arul M Chinnaiyan; Maryam Fouladi; Nicholas G Gottardo; Carl Koschmann
Journal:  Acta Neuropathol Commun       Date:  2018-07-26       Impact factor: 7.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.